Single-agent capecitabin maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of mCRC

被引：0
|
作者：
Xu, R. [1 ]
Li, Y. [1 ]
Luo, H. [1 ]
Wang, W. [2 ]
Wang, Z. [1 ]
Yuan, X. [3 ]
Ma, D. [4 ]
Wang, F. H. [1 ]
Zhang, D. [1 ]
Lin, D. R. [5 ,6 ]
Jia, J.
Hu, X. H. [7 ]
Peng, J. W. [8 ]
Lin, Y. C. [9 ]
机构：
[1] Sun Yat Sen Univ, Ctr Canc, Med Oncol, Guangzhou 510275, Guangdong, Peoples R China
[2] Foshan 1 Peoples Hosp, Med Oncol, Foshan, Peoples R China
[3] Huizhou Cent Hosp, Med Oncol, Huizhou, Peoples R China
[4] Guangdong Gen Hosp, Med Oncol, Huizhou, Peoples R China
[5] Jiangmen Cent Hosp, Med Oncol, Jiangmen, Peoples R China
[6] Dongguan Peoples Hosp, Med Oncol, Dongguan, Peoples R China
[7] Guangxi Med Univ, Canc Hosp, Med Oncol, Nanning, Peoples R China
[8] Zhongshan Peoples Hosp, Med Oncol, Zhongshan, Peoples R China
[9] Shantou Univ, Canc Hosp, Med Oncol, Shantou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
142O
引用
收藏
页码：43 / 43
页数：1
相关论文
共 50 条
  • [41] Pseudoprogression in patients with uterine leiomyosarcoma treated with first-line single-agent doxorubicin
    Howroyd, Lucy-Rose
    Cornell, Isabel
    Benson, Charlotte
    Napolitano, Andrea
    Blackledge, Matthew
    Sumhonmun, Timothy
    Moskovic, Eleanor
    Kelly-Morland, Christian
    Adejolu, Margaret
    Jones, Robin L.
    Messiou, Christina
    EUROPEAN JOURNAL OF CANCER, 2023, 192
  • [42] Capecitabine and oxaliplatin (XELOX) as first-line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC)
    Salud, A.
    Escudero, P.
    Feliu, J.
    Lopez-Gomez, L.
    Bolanos, M.
    Galan, A.
    Yubero, A.
    Vicent, J. M.
    Losa, F.
    Gonzalez-Baron, M.
    EJC SUPPLEMENTS, 2005, 3 (02): : 190 - 190
  • [43] A comparison of medical resource use for 4 chemotherapy regimens as first-line treatment for metastatic colorectal cancer (MCRC): XELOX vs. FOLFOX4 ± bevacizumab (A)
    Scheithauer, W.
    Cassidy, J.
    Figer, A.
    Wong, R.
    Koski, S.
    Lichinitser, M.
    Yang, T.
    Clarke, S.
    Diaz-Rubio, E.
    Garrison, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [44] Prognostic Factors in Japanese Patients with Advanced Pancreatic Cancer Treated with Single-agent Gemcitabine as First-line Therapy
    Tanaka, Tsutomu
    Ikeda, Masafumi
    Okusaka, Takuji
    Ueno, Hideki
    Morizane, Chigusa
    Hagihara, Atsushi
    Iwasa, Satoru
    Kojima, Yasushi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (11) : 755 - 761
  • [45] Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer
    Arteaga, CL
    BREAST CANCER RESEARCH, 2003, 5 (02) : 96 - 100
  • [46] Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer
    Carlos L Arteaga
    Breast Cancer Research, 5
  • [47] First-line, single-agent Herceptin® (trastuzumab) in metastatic breast cancer:: a preliminary report
    Vogel, C
    Cobleigh, MA
    Tripathy, D
    Gutheil, JC
    Harris, LN
    Fehrenbacher, L
    Slamon, DJ
    Murphy, M
    Novotny, WF
    Burchmore, M
    Shak, S
    Stewart, SJ
    EUROPEAN JOURNAL OF CANCER, 2001, 37 : S25 - S29
  • [48] XELOX compared to FOLFOX4: Survival and response results from XELOX-1/ NO16966, a randomized phase III trial of first-line treatment for patients with metastatic colorectal cancer (MCRC)
    Cassidy, J.
    Clarke, S.
    Diaz-Rubio, E.
    Scheithauer, W.
    Figer, A.
    Wong, R.
    Koski, S.
    Lichinitser, M.
    Yang, T.
    Saltz, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [49] PHARMACOECONOMIC ANALYSIS OF DIRECT MEDICAL COSTS OF METASTATIC COLORECTAL CANCER THERAPY WITH XELOX OR FOLFOX4 WITH OR WITHOUT BEVACIZUMAB AS THE FIRST-LINE TREATMENT
    Tikhomirova, A.
    Kulikov, A.
    Yagudina, R.
    VALUE IN HEALTH, 2010, 13 (07) : A267 - A267
  • [50] XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
    J Cassidy
    S Clarke
    E Díaz-Rubio
    W Scheithauer
    A Figer
    R Wong
    S Koski
    K Rittweger
    F Gilberg
    L Saltz
    British Journal of Cancer, 2011, 105 : 58 - 64
12345